FdaApplication
NDA 022545
Identifiers
- fda_app_no: NDA022545
Properties
| Property | Value |
|---|---|
| applicant_name | NOVARTIS PHARMACEUTICALS CORP |
| application_type | NDA |
| approval_date | 2010-08-26 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TEKAMLO | ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE | EQ 300MG BASE;EQ 10MG BASE | TABLET;ORAL |
| TEKAMLO | ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE | EQ 300MG BASE;EQ 5MG BASE | TABLET;ORAL |
| TEKAMLO | ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE | EQ 150MG BASE;EQ 5MG BASE | TABLET;ORAL |
| TEKAMLO | ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE | EQ 150MG BASE;EQ 10MG BASE | TABLET;ORAL |
4 products